Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives

References

• Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol. 2007;6(10):903–912.
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–286.
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain. 2006;129(Pt 3):595–605.
   PubMed Web of Science ®Google Scholar
• Cottrell DA, Kremenchutzky M, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain. 1999;122(Pt 4):625–639.
   PubMed Web of Science ®Google Scholar
• Gajofatto A, Calabrese M, Benedetti MD, et al. Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. Dis Markers. 2013;35(6):687–699.
   PubMed Web of Science ®Google Scholar
• Tremlett H, Zhao Y, Rieckmann P, et al. New perspectives in the natural history of multiple sclerosis. Neurology. 2010;74(24):2004–2015.
   PubMed Web of Science ®Google Scholar
• Lassman H. Multiple sclerosis: is there neurodegeneration independent from inflammation? J Neurol Sci. 2007;259(1–2):3–6.
   PubMed Web of Science ®Google Scholar
• Ontaneda D, Fox RJ. Progressive multiple sclerosis. Curr Opin Neurol. 2015;28(3):237–243.
   PubMed Web of Science ®Google Scholar
• Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47(6):707–717.
   PubMed Web of Science ®Google Scholar
• Lassmann H. The architecture of inflammatory demyelinating lesions: implications for studies on pathogenesis. Neuropathol Appl Neurobiol. 2011;37(7):698–710.
   PubMed Web of Science ®Google Scholar
• Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128(Pt 11):2705–2712.
   PubMed Web of Science ®Google Scholar
• Gilmore CP, Bo L, Owens T, et al. Spinal cord gray matter demyelination in multiple sclerosis: a novel pattern of residual plaque morphology. Brain Pathol. 2006;16(3):202–208.
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol. 1991;29(1):53–62.
   PubMed Web of Science ®Google Scholar
• Ingle GT, Stevenson VL, Miller DH, et al. Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain. 2003;126(Pt 11):2528–2536.
   PubMed Web of Science ®Google Scholar
• Sastre-Garriga J, Ingle GT, Chard DT, et al. Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis. Neuroimage. 2004;22(1):353–359.
   PubMed Web of Science ®Google Scholar
• Stevenson VL, Leary SM, Losseff NA, et al. Spinal cord atrophy and disability in MS: a longitudinal study. Neurology. 1998;51(1):234–238.
   PubMed Web of Science ®Google Scholar
• Bieniek M, Altmann DR, Davies GR, et al. Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006;77(9):1036–1039.
   PubMed Web of Science ®Google Scholar
• Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI study group. Neurology. 2000;54(5):1145–1155.
   PubMed Web of Science ®Google Scholar
• Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol. 1995;37(1):30–40.
   PubMed Web of Science ®Google Scholar
• Sipe JC, Romine JS, Koziol JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet. 1994;344(8914):9–13.
   PubMed Web of Science ®Google Scholar
• Milanese C, La Mantia L, Salmaggi A, et al. A double blind study on azathioprine efficacy in multiple sclerosis: final report. J Neurol. 1993;240(5):295–298.
   PubMed Web of Science ®Google Scholar
• Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast cooperative multiple sclerosis treatment group. Neurology. 1993;43(5):910–918.
   PubMed Web of Science ®Google Scholar
• Likosky WH, Fireman B, Elmore R, et al. Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry. 1991;54(12):1055–1060.
   PubMed Web of Science ®Google Scholar
• The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet. 1991;337(8739):441–446.
   PubMed Web of Science ®Google Scholar
• The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol. 1990;27(6):591–605.
   PubMed Web of Science ®Google Scholar
• British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet. 1988;2(8604):179–183.
   PubMed Web of Science ®Google Scholar
• Ellison GW, Myers LW, Mickey MR, et al. A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology. 1989;39(8):1018–1026.
   PubMed Web of Science ®Google Scholar
• Kappos L, Patzold U, Dommasch D, et al. Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis: results of the German multicenter study. Ann Neurol. 1988;23(1):56–63.
   PubMed Web of Science ®Google Scholar
• Goodkin DE, Plencner S, Palmer-Saxerud J, et al. Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs nonmaintenance therapy. Arch Neurol. 1987;44(8):823–827.
   PubMedGoogle Scholar
• Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983;308(4):173–180.
   PubMed Web of Science ®Google Scholar
• Patzold U, Hecker H, Pocklington P. Azathioprine in treatment of multiple sclerosis. Final results of a 4 1/2-year controlled study of its effectiveness covering 115 patients. J Neurol Sci. 1982;54(3):377–394.
   PubMed Web of Science ®Google Scholar
• Montalban X, Sastre-Garriga J, Tintore M, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler. 2009;15(10):1195–1205.
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Narayana PA, O’Connor P, et al. Glatiramer Acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007;61(1):14–24.
   PubMed Web of Science ®Google Scholar
• Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology. 2003;60(1):44–51.
   PubMed Web of Science ®Google Scholar
• Bornstein MB, Miller A, Slagle S, et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology. 1991;41(4):533–539.
   PubMed Web of Science ®Google Scholar
• Kastrukoff LF, Oger JJ, Hashimoto SA, et al. Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation. Neurology. 1990;40(3 Pt 1):479–486.
   PubMed Web of Science ®Google Scholar
• Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10023):1075–1084.
   PubMed Web of Science ®Google Scholar
• Montalban X, Hemmer B, Rammohan K, et al. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis: results of the placebo-controlled, double-blind, Phase III ORATORIO study. Mult Scler. 2015;21(S11):781–782. Presented at: 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Barcelona, Spain, 7-10 October 2015.
   Google Scholar
• Karussis D, Shor H, Yachnin J, et al. T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial. PLoS One. 2012;7(12):e50478.
   PubMed Web of Science ®Google Scholar
• Hawker K, O’Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66(4):460–471.
   PubMed Web of Science ®Google Scholar
• Pöhlau D, Przuntek H, Sailer M, et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler. 2007;13(9):1107–1117.
   PubMed Web of Science ®Google Scholar
• Warren KG, Catz I, Ferenczi LZ, et al. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol. 2006;13(8):887–895.
   PubMed Web of Science ®Google Scholar
• Rostami AM, Sater RA, Bird SJ, et al. A double-blind, placebo-controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis. Mult Scler. 1999;5(3):198–203.
   PubMed Web of Science ®Google Scholar
• Cook SD, Devereux C, Troiano R, et al. Modified total lymphoid irradiation and low dose corticosteroids in progressive multiple sclerosis. J Neurol Sci. 1997;152(2):172–181.
   PubMed Web of Science ®Google Scholar
• Cazzato G, Mesiano T, Antonello R, et al. Double-blind, placebo-controlled, randomized, crossover trial of high-dose methylprednisolone in patients with chronic progressive form of multiple sclerosis. Eur Neurol. 1995;35(4):193–198.
   PubMed Web of Science ®Google Scholar
• Wiles CM, Omar L, Swan AV, et al. Total lymphoid irradiation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1994;57(2):154–163.
   PubMed Web of Science ®Google Scholar
• Cook SD, Devereux C, Troiano R, et al. Effect of total lymphoid irradiation in chronic progressive multiple sclerosis. Lancet. 1986;1(8495):1405–1409.
   PubMed Web of Science ®Google Scholar
• Khatri BO, McQuillen MP, Harrington GJ, et al. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology. 1985;35(3):312–319.
   PubMed Web of Science ®Google Scholar
• Gordon PA, Carroll DJ, Etches WS, et al. A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis. Can J Neurol Sci. 1985;12(1):39–44.
   PubMed Web of Science ®Google Scholar
• Miller H, Newell DJ, Ridley A. Multiple sclerosis. Trials of maintenance treatment with prednisolone and soluble aspirin. Lancet. 1961;1(7169):127–129.
   PubMed Web of Science ®Google Scholar
• Tourbah A, Lebrun-Frenay C, Edan G, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study. Mult Scler. 2016 Sep;1:pii: 1352458516667568. Epub ahead of print.
   Google Scholar
• Schreiber K, Magyari M, Sellebjerg F, et al. High-dose erythropoietin in patients with progressive multiple sclerosis: a randomized, placebo-controlled, phase 2 trial. Mult Scler. 2016 Aug;1:pii: 1352458516661048. Epub ahead of print.
   Google Scholar
• Mostert J, Heersema T, Mahajan M, et al. The effect of fluoxetine on progression in progressive multiple sclerosis: a double-blind, randomized, placebo-controlled trial. ISRN Neurol. 2013 Jul;29(2013):370943.
   Google Scholar
• Zajicek J, Ball S, Wright D, et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol. 2013;12(9):857–865.
   PubMed Web of Science ®Google Scholar
• Vermersch P, Benrabah R, Schmidt N, et al. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol. 2012 Jun;12(12):36.
   PubMed Web of Science ®Google Scholar
• Karpha I, Ramtahal J, Boggild M, et al. A single-centre, pilot, randomised controlled trial of recombinant human erythropoietin in primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010;81(11):e30. Presented at: ABN Annual Meeting. Bournemonth, United Kingdom, 11-14 May 2010.
   Google Scholar
• Noseworthy JH, O’Brien P, Erickson BJ, et al. The mayo clinic-Canadian cooperative trial of sulfasalazine in active multiple sclerosis. Neurology. 1998;51(5):1342–1352.
   PubMed Web of Science ®Google Scholar
• Milligan NM, Miller DH, Compston DA. A placebo-controlled trial of isoprinosine in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 1994;57(2):164–168.
   PubMed Web of Science ®Google Scholar
• Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry. 1997;62(2):112–118.
   PubMed Web of Science ®Google Scholar
• Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol. 1997;244(3):153–159.
   PubMed Web of Science ®Google Scholar
• Hartung HP, Gonsette R, König N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360(9350):2018–2025.
   PubMed Web of Science ®Google Scholar
• Beutler E, Sipe JC, Romine JS, et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A. 1996;93(4):1716–1720.
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Schrempf W. Glatiramer acetate: mechanisms of action in multiple sclerosis. Int Rev Neurobiol. 2007;79:537–570.
   PubMed Web of Science ®Google Scholar
• Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo- controlled trial. UBC MS/MRI study group and the IFNB multiple sclerosis study group. Neurology. 1993;43(4):662–667.
   PubMed Web of Science ®Google Scholar
• European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352(9139):1491–1497.
   PubMed Web of Science ®Google Scholar
• Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Clinical results. Neurology. 2001;56(11):1496–1504.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002;59(5):679–687.
   PubMed Web of Science ®Google Scholar
• Panitch H, Miller A, Paty D, et al. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63(10):1788–1795.
   PubMed Web of Science ®Google Scholar
• Longbrake EE, Cross AH. Effect of multiple sclerosis disease-modifying therapies on b cells and humoral immunity. JAMA Neurol. 2016 Feb;73(2):219–225.
   PubMed Web of Science ®Google Scholar
• Gajofatto A, Turatti M, Monaco S, et al. Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis. Drug Healthc Patient Saf. 2015;7:157–167.
   PubMedGoogle Scholar
• Kappos L, Bar-Or A, Cree B, et al. Efficacy and safety of siponimod in secondary progressive multiple sclerosis - results of the placebo controlled, double-blind, phase III EXPAND study. Mult Scler. 2016;22(S3):828–829. Presented at: 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis. London, United Kingdom, 14-17 September 2016.
   Google Scholar
• Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33(2):91–101.
   PubMed Web of Science ®Google Scholar
• Freedman MS, Bar-Or A, Oger J, et al. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology. 2011;77(16):1551–1560.
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Fischer B, Norra C, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain. 2007;130(Pt 10):2577–2588.
   PubMed Web of Science ®Google Scholar
• Peyro Saint Paul L, Debruyne D, Bernard D, et al. Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis. Expert Opin Drug Metab Toxicol. 2016;12(3):327–344.
   PubMed Web of Science ®Google Scholar
• Sedel F, Papeix C, Bellanger A, et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord. 2015;4(2):159–169.
   PubMed Web of Science ®Google Scholar
• Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 2015;14(2):208–223.
   PubMed Web of Science ®Google Scholar
• McMurran CE, Jones CA, Fitzgerald DC, et al. CNS remyelination and the innate immune system. Front Cell Dev Biol. 2016;4:38.
   PubMedGoogle Scholar
• Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. national multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology. 1996;46(4):907–911.
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol. 2000;47(6):831–835.
   PubMed Web of Science ®Google Scholar
• Invernizzi P, Benedetti MD, Poli S, et al. Azathioprine in multiple sclerosis. Mini Rev Med Chem. 2008;8(9):919–926.
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(Pt 3):606–616.
   PubMed Web of Science ®Google Scholar
• Kragt JJ, Thompson AJ, Montalban X, et al. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurology. 2008;70:1084–1091.
   PubMed Web of Science ®Google Scholar
• Choi SR, Howell OW, Carassiti D, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain. 2012;135(Pt 10):2925–2937.
   PubMed Web of Science ®Google Scholar
• Calabrese M, Magliozzi R, Ciccarelli O, et al. Exploring the origins of grey matter damage in multiple sclerosis. Nat Rev Nurosci. 2015;16(3):147–158.
   PubMed Web of Science ®Google Scholar
• Shirani A, Okuda DT, Stuve O. Therapeutic advances and future prospects in progressive forms of multiple sclerosis. Neurotherapeutics. 2016;13(1):58–69.
   PubMed Web of Science ®Google Scholar
• Harlow DE, Honce JM, Miravalle AA. Remyelination therapy in multiple sclerosis. Front Neurol. 2015;6:257.
   PubMed Web of Science ®Google Scholar
• Mi S, Lee X, Shao Z, et al. LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat Neurosci. 2004;7:221–228.
   PubMed Web of Science ®Google Scholar
• Aktas O, Vanopdenbosch L, Comi G, et al. Anti-LINGO-1 monoclonal antibody BIIB033 improves optic nerve latency in acute optic neuritis: primary efficacy analysis of the RENEW study. Mult Scler. 2015;21(S11):52. Presented at: 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Barcelona, Spain, 7-10 October 2015.
   Google Scholar
• Cadavid D, Edwards KR, Hupperts R, et al. Efficacy analysis of opicinumab in relapsing multiple sclero- sis: the phase 2b SYNERGY trial. Mult Scler. 2016;22(S3):66. Presented at: 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis. London, United Kingdom, 14-17 September 2016.
   Google Scholar
• Vollmer TL, Sørensen PS, Selmaj K, et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol. 2014;261:773–783.
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA, Pagani E, et al. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry. 2014;85(8):851–858.
   PubMed Web of Science ®Google Scholar
• Orack JC, Deleidi M, Pitt D, et al. Concise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegeneration. Stem Cells Transl Med. 2015;4(3):252–260.
   PubMed Web of Science ®Google Scholar
• Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012;11:150–156.
   PubMed Web of Science ®Google Scholar